For the quarter ending 2025-09-30, CDNA had $23,223K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 100,055 | - |
| Cost of test services, product, and patient and digital solutions-Service | 14,058 | - |
| Cost of test services, product, and patient and digital solutions-Product | 5,131 | - |
| Cost of test services, product, and patient and digital solutions-Patient And Digital Solutions | 10,050 | - |
| Personnel cost | 33,915 | - |
| Professional and legal fees | 10,307 | - |
| Research materials and clinical trials expense | 1,791 | - |
| Depreciation and amortization expense | 3,020 | - |
| Stock-based compensation expense | 8,418 | - |
| Litigation settlement expense | 0 | - |
| Transformational initiative costs | 2,395 | - |
| Other segment items | 13,179 | - |
| Interest income, net | 2,013 | - |
| Net loss | 1,675 | -18,921 |
| Stock-based compensation | 8,418 | 18,355 |
| Depreciation and amortization | 3,814 | 7,322 |
| Impairment of intangible asset and associated construction in progress | 2,258 | - |
| Amortization of right-of-use assets | 1,349 | 2,671 |
| Revaluation of contingent consideration to estimated fair value | 0 | 547 |
| Amortization of premium on short-term marketable securities, net | -931 | -562 |
| Other non-cash operating activities | -55 | 7 |
| Accounts receivable | -19,551 | 2,336 |
| Inventory | 252 | 6,741 |
| Prepaid and other assets | 4,189 | 4,170 |
| Operating leases liabilities, net | -1,502 | -2,953 |
| Accounts payable | 1,561 | 1,625 |
| Accrued compensation | 3,865 | -19,303 |
| Accrued and other liabilities | -2 | 5,544 |
| Change in deferred revenue | -174 | 1,116 |
| Change in deferred taxes | 0 | 0 |
| Net cash provided by operating activities | 37,358 | -16,689 |
| Acquisitions of intangible asset | 675 | - |
| Purchases of short-term marketable securities | 17,071 | 67,280 |
| Maturities of short-term marketable securities | 31,400 | 94,639 |
| Additions of capital expenditures | 1,305 | 2,637 |
| Net cash provided by investing activities | 12,349 | 24,722 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 2,272 |
| Taxes paid related to net share settlement of restricted stock units | 1,147 | 9,304 |
| Proceeds from exercise of stock options | 232 | 4,078 |
| Payment of contingent consideration | 0 | 1,500 |
| Repurchase and retirement of common stock | 25,563 | 50,000 |
| Net cash used in financing activities | -26,478 | -54,454 |
| Effect of exchange rate changes on cash and cash equivalents | -6 | -90 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 23,223 | -46,511 |
| Cash and cash equivalents at beginning of period | 115,274 | - |
| Cash and cash equivalents at end of period | 91,986 | - |
CareDx, Inc. (CDNA)
CareDx, Inc. (CDNA)